Pierre and Marie Curie University

X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

Retrieved on: 
Tuesday, August 8, 2023
University, Interim, Assistance Publique–Hôpitaux de Paris, Drug development, Roche, Therapy, WHIM, Harvard University, Salk Institute for Biological Studies, Biogen, Hospital, MBA, Research, CMO, Doctor of Philosophy, Merck & Co., Rutgers University, Pierre and Marie Curie University, X4, Boehringer Ingelheim, MD, Patient, WHIM syndrome, Immune system, Growth, Rare, Pharmaceutical industry, Ligand Pharmaceuticals

“We are thrilled to welcome Christophe to our leadership team at this exciting time at X4,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.

Key Points: 
  • “We are thrilled to welcome Christophe to our leadership team at this exciting time at X4,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • We would also like to thank Dr. Murray Stewart, who has been serving as our Interim Chief Medical Officer, for his exceptional contributions and his leadership.
  • The company has made great progress and I look forward to adding to its continued forward momentum.
  • He received his MD and PhD in internal medicine/endocrinology-metabolism from the University of Paris, France, and completed his MBA at Rutgers University.

DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president

Retrieved on: 
Tuesday, May 16, 2023
Vaccine, Molecular biology, Hanmi, Hanyang University, Broad Institute, RA, Diabetes, Biochemistry, Catholic higher education, Pharming, National university, RXR Realty, Haemophilus influenzae, Korea University, Ministry of Food and Drug Safety, Cancer, Lead, Medicine, Research, Multimedia, MIT, Pierre and Marie Curie University, Veteran, Harvard University, Bangladesh Technical Education Board, Harvard Medical School, Certification, Organization, Ministry, Core Group, CLIA, Acquisition, Cervical cancer, Seoul National University, Institut Pasteur Korea, Growth, FDA, IND, Pharmaceutical industry, Management, Food

SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointed Yong Gu Lee as the new CEO and Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president. Drawing on the expertise of sales veterans who have more than 30 years of experience, the company plans to actively reorganize the global sales networks, launch new products and further enhance its capabilities to get global approvals for new drugs.

Key Points: 
  • SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointed Yong Gu Lee as the new CEO and Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president.
  • The new CEO, Yong Gu Lee, graduated from Hanyang University.
  • Co., Ltd., managing director of the healthcare business division at Beijing Medi'Care Co., Ltd and vice president of the COREE Group.
  • New president Kevin Kwon will be appointed as a board director from a shareholders' meeting.

Concerto Biosciences Announces Strategic Business Development Hire

Retrieved on: 
Monday, February 6, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, MBA, Cold medicine, Master of Business Administration, Master of Science, Sanofi Pasteur, Head, Biochemistry, Peter Wall Institute for Advanced Studies, Pierre and Marie Curie University, Household, Business administration, Agriculture, Partnership, Master of Advanced Studies, Environment, Business development, Microbiology, Fine chemical, Northeastern University, Concerto

Concerto Biosciences, a biotechnology company designing microbial communities that restore health to our bodies and our environment, announced today that it has appointed Didier Vingadassalom, Ph.D., MBA, as Senior Director, Business Development.

Key Points: 
  • Concerto Biosciences, a biotechnology company designing microbial communities that restore health to our bodies and our environment, announced today that it has appointed Didier Vingadassalom, Ph.D., MBA, as Senior Director, Business Development.
  • He will be responsible for maturing the team’s business development infrastructure, evaluating co-discovery and co-development partnership opportunities, and helping prioritize internal technology development directions from a business development perspective.
  • “Didier has both a deep scientific background and years of business development experience— a potent combination and a perfect match for Concerto as our first senior director of business development,” said Cheri Ackerman, CEO of Concerto.
  • “Our science team already excels at rapidly discovering optimized microbial products with our kChip platform, and Didier will help us point that unique capability at pressing, high-value opportunities in collaboration with our partners.”
    Prior to joining Concerto Biosciences, Vingadassalom was senior director, business development and head of alliance management, SQZ Biotechnologies.

The Canadian Vaping Association: Nicotine doesn’t cause cancer

Retrieved on: 
Thursday, June 9, 2022
Nicotine, Pierre and Marie Curie University, Oncology, HTPS, Cancer Research UK, NRT, Smoking, Smoker, Pierre, Awareness, CVA, La, Physician, GLOBE, Risk, Herbal cigarette, Adoption, Lung cancer, Cancer, Tobacco

Smoking is responsible for almost 9 out of 10 cases of lung cancer and known to cause various other forms of cancer.

Key Points: 
  • Smoking is responsible for almost 9 out of 10 cases of lung cancer and known to cause various other forms of cancer.
  • He also noted the conclusion of Cancer Research UK, Nicotine does not cause cancer, and people have used nicotine replacement therapy safely for many years.
  • It is unsurprising that myths about nicotine persist as surveys find most physicians still perceive nicotine as cancer causing.
  • Additionally, there is a lack of awareness that vaping products are a less harmful source of nicotine for those who switch to vaping.

Stablix Appoints Eddine Saiah Chief Scientific Officer and Expands Leadership Team

Retrieved on: 
Thursday, May 26, 2022
Biotechnology, Pharmaceutical, Health, Senior, Chemistry, NEA, Inflammation, Pain, Investment, COO, Doctor of Philosophy, Mayo Clinic, CSO, Drug discovery, Leadership, Dub, MTORC1, Degenerative disease, Physiology, Clinical professor, Pfizer, Depression, Ubiquitin, Research, Neurodegeneration, Lists of diseases, CNS, TPS, Wyeth, Mark (given name), Columbia University Vagelos College of Physicians and Surgeons, Protein, Cancer, Pierre and Marie Curie University, Pharmaceutical industry, Pharmacology

Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced that Eddine Saiah, Ph.D., has joined the company as Chief Scientific Officer.

Key Points: 
  • Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced that Eddine Saiah, Ph.D., has joined the company as Chief Scientific Officer.
  • Dr. Saiah has co-authored more than 120 scientific publications, patents, reviews and presentations.
  • In addition, Stablix announced that Dr. Kevin Sprott, Ph.D., has been promoted to Chief Operating Officer from Senior Vice President, Drug Discovery.
  • The appointment of Eddine as CSO and Kevin as COO significantly expands our executive leadership team and makes a strong statement about our commitment to build a world-class innovative company, said Stablixs CEO Tony Kingsley.

Odile Jacob Publishing to release today The Science of Light, a captivating journey of scientific discovery by Nobel Prize-winning physicist Serge Haroche

Retrieved on: 
Wednesday, March 30, 2022
Newton, Max Planck Institute for the Science of Light, Method, Multimedia, Haroche, Science, Invention, Harvard University, Nobel Prize in Physics, View, Nobel Prize, Pierre and Marie Curie University, Paris, Time, Yale University, Microscope, Physics, Galileo Galilei, Light

Light has fascinated mankind since the dawn of time.

Key Points: 
  • Light has fascinated mankind since the dawn of time.
  • Placing his own career in a rich lineage of scientific discovery, Nobel Prizewinningphysicist Serge Haroche offers a literally enlightening account of what we know about light today, how we learned it, and how that knowledgehas led to countless inventions that have revolutionized daily life.
  • A uniquely captivating book about the thrill of discovery.
  • He has taught at Paris VI University, the cole Polytechnique, the cole Normale Suprieure, Harvard University, and Yale University.

Odile Jacob Publishing to release today The Science of Light, a captivating journey of scientific discovery by Nobel Prize-winning physicist Serge Haroche

Retrieved on: 
Wednesday, March 30, 2022
Newton, Max Planck Institute for the Science of Light, Method, Haroche, Science, Invention, Harvard University, Nobel Prize in Physics, Nobel Prize, Pierre and Marie Curie University, Paris, Time, Yale University, Microscope, Physics, Galileo Galilei, Light

Light has fascinated mankind since the dawn of time.

Key Points: 
  • Light has fascinated mankind since the dawn of time.
  • Placing his own career in a rich lineage of scientific discovery, Nobel Prizewinningphysicist Serge Haroche offers a literally enlightening account of what we know about light today, how we learned it, and how that knowledgehas led to countless inventions that have revolutionized daily life.
  • A uniquely captivating book about the thrill of discovery.
  • He has taught at Paris VI University, the cole Polytechnique, the cole Normale Suprieure, Harvard University, and Yale University.

Lysogene Provides Medical Update

Retrieved on: 
Monday, February 7, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Adaptive clinical trial, Glycogen storage disease, Lists of diseases, Forward-looking statement, GM1, Fragile X syndrome, AP-HP, Competition and Markets Authority, Company, CNS, Neurology, MPS, Clinical trial, Neurodegeneration, Knowledge, Patient, Safety, LYS, Autism, Central nervous system, Cros, CEO, Pierre and Marie Curie University, GM1 gangliosidoses, A-DNA, Child, Pierre, Pharmaceutical industry

Lysogene (FR0013233475 LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today provides a medical update.

Key Points: 
  • Lysogene (FR0013233475 LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today provides a medical update.
  • First, Lysogene has dosed the first patient in France with LYS-GM101 investigational gene therapy at the Armand Trousseau Hospital (AP-HP).
  • Second, Lysogene has appointed a seasoned Chief Medical Officer, Dr. Marie Trad, effective February 1st, 2022.
  • Karen Aiach, Chairman and CEO of Lysogene will present preliminary safety data from the ongoing adaptive clinical study in children with GM1 gangliosidosis.

Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Françon PhD as Chief Operating Officer

Retrieved on: 
Monday, November 15, 2021
Sartorius, Pierre and Marie Curie University, University, McGill University, Industry, Therapy, Novartis, CEO, Disease, Doctor of Philosophy, Roche, Technology, Neurological disorder, Degenerative disease, Goal, Research, Swiss Society for Optics and Microscopy, CNS, Company, IPO, University of Zurich, Central nervous system, Nasdaq, Patient, Molecular and Cellular Biology, CMC, Bristol Myers Squibb, Pharmaceutical industry, Medicine, Fine chemical, Vaccine

"I am very pleased to welcome Thomas and Patricia to the leadership team at Coave.

Key Points: 
  • "I am very pleased to welcome Thomas and Patricia to the leadership team at Coave.
  • Dr Blaettler is an expert in the neuroscience therapy area, having over 25 years' experience in the field, both in clinical residency and industry.
  • Thomas joins Coave from Orphazyme A/Swhere, since 2016, he served as Chief Medical Officer and was responsible for devising the clinical development strategy and progressing the company's rare neurodegenerative pipeline.
  • Patricia obtained her PhD in Molecular and Cellular Biology from Paris VI University and completed postdoctoral research at McGill University.

Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Françon PhD as Chief Operating Officer

Retrieved on: 
Monday, November 15, 2021
Sartorius, Pierre and Marie Curie University, University, McGill University, Industry, Therapy, Novartis, CEO, Disease, Doctor of Philosophy, Roche, Technology, Neurological disorder, Degenerative disease, Goal, Research, Swiss Society for Optics and Microscopy, CNS, Company, IPO, University of Zurich, Central nervous system, Nasdaq, Patient, Molecular and Cellular Biology, CMC, Bristol Myers Squibb, Pharmaceutical industry, Medicine, Fine chemical, Vaccine

PARIS, Nov. 15, 2021 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, today announced that it has strengthened its leadership team with the appointments of Thomas Blaettler MD, as Chief Medical Officer, and Patricia Françon PhD, to the newly created position of Chief Operating Officer.

Key Points: 
  • "I am very pleased to welcome Thomas and Patricia to the leadership team at Coave.
  • Dr Blaettler is an expert in the neuroscience therapy area, having over 25 years' experience in the field, both in clinical residency and industry.
  • Thomas joins Coave from Orphazyme A/Swhere, since 2016, he served as Chief Medical Officer and was responsible for devising the clinical development strategy and progressing the company's rare neurodegenerative pipeline.
  • Patricia obtained her PhD in Molecular and Cellular Biology from Paris VI University and completed postdoctoral research at McGill University.